EIGR Eiger BioPharmaceuticals Inc.

7.67
+0.52  (+7%)
Previous Close 7.16
Open 7.35
Price To Book 3.34
Market Cap 188,490,532
Shares 24,559,027
Volume 202,285
Short Ratio
Av. Daily Volume 386,901
Stock charts supplied by TradingView

NewsSee all news

  1. Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic

    PALO ALTO, Calif., April 1, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  2. Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

    PALO ALTO,  Calif., March 23, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  3. Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    PALO ALTO, Calif., March 13, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  4. Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

    PALO ALTO, Calif., Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for

  5. Eiger Updates on 2019 Progress and 2020 Milestones Expected

    PALO ALTO, Calif., Jan. 6, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released October 16, 2018 - endpoints met. Data presented at ENDO March 25, 2019.
Avexitide (Exendin 9-39)
Post-Bariatric Hypoglycemia (PBH)
Phase 3 enrolment to be completed in 2021. Delayed due to COVID-19.
Lonafarnib - D-LIVR
Chronic hepatitis delta virus (HDV)
Phase 2 trial did not meet endpoints - January 16, 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 data released October 16, 2018 did not meet endpoints.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
MYDICAR - CUPID 2 Trial
Ischemic or dilated cardiomyopathy
Phase 2 additional data expected at EASL and AASLD 2020
Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - LIFT
Hepatitis delta virus (HDV)
NDA submission has been completed - noted March 23, 2020.
Lonafarnib
Hutchinson-Gilford Progeria Syndrome (HGPS)

Latest News

  1. Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic

    PALO ALTO, Calif., April 1, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  2. Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

    PALO ALTO,  Calif., March 23, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  3. Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    PALO ALTO, Calif., March 13, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  4. Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

    PALO ALTO, Calif., Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for

  5. Eiger Updates on 2019 Progress and 2020 Milestones Expected

    PALO ALTO, Calif., Jan. 6, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare

  6. Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

    PALO ALTO, Calif., Dec. 16, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for

  7. Eiger to Present at Jefferies 2019 London Healthcare Conference

    PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  8. Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019

    PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare

  9. Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    PALO ALTO, Calif., Nov. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  10. Eiger to Present at Cantor 2019 Global Healthcare Conference

    PALO ALTO, Calif., Sept. 27, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  11. Eiger BioPharmaceuticals to Participate in September Conferences

    PALO ALTO, Calif., Aug. 29, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today